Laboratory assessment of the antimycotic drug clotrimazole.
Laboratory studies on clotrimazole showed that it had marked activity in vitro against all the Candida spp. and Cryptococcus spp. tested, against almost all strains of dermatophytes, and against Aspergillus spp and other fungal genera responsible for systemic mycoses; it had limited activity towards Gram-positive bacteria. The majority of Candida strains required MICs below 1 mug/ml and MCCs below 2 mug/ml.Serum, urine, and faecal assays of clotrimazole were made by microbiological methods on five children who received 100 mg/kg/day clotrimazole for several weeks. In-vitro sensitivity tests and biological fluid drug assays are also reported on specimens from 18 patients in other hospitals receiving clotrimazole for severe candidosis; several were renal transplant cases. Similar investigations are reported on specimens from 18 patients with pulmonary aspergilloses. The significance of low levels of the drug in body fluids, even after prolonged therapy, is discussed, and it is suggested that clotrimazole may be the first of a long series of imidazole derivatives with varying pharmacological and therapeutic properties.
D000935:Antifungal Agents / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use / Q000652:urine; D001230:Aspergillus / Q000187:drug effects; D001555:Benzene Derivatives / Q000494:pharmacology; D002175:Candida / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy; D003454:Cryptococcus / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use / Q000652:urine; D007223:Infant; D008826:Microbial Sensitivity Tests; D009154:Mutation
D000935:Antifungal Agents; D001555:Benzene Derivatives; D007093:Imidazoles